BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-18@catalystbrief.girapphe.com
DTSTAMP:20261117T061546Z
LAST-MODIFIED:20261117T061546Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Hoffmann-La Roche — Ranibizumab [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study of the Efficacy\, Safety\, 
 and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery Sys
 tem With Ranibizumab in Patients With Neovascular Age-Related Macular Dege
 neration (Velodrome).\nSource: https://clinicaltrials.gov/study/NCT0465728
 9\nhttps://catalystbrief.girapphe.com/e/18?lang=en\nNot investment advice.
  Dates may change.
URL:https://catalystbrief.girapphe.com/e/18?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
